share_log

MindBio Is Exploring Dual Listing on A Senior Exchange With Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3

MindBio Is Exploring Dual Listing on A Senior Exchange With Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3

MindBio正在探索在高級交易所進行雙重上市,在積極的試驗數據支持下,正在進行多項2B期臨床試驗,並計劃進行第三階段
Accesswire ·  05/01 17:20

VANCOUVER, BC / ACCESSWIRE / May 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to announce that it has been presenting MindBio to various parties, institutional investment firms and brokerage firms for a potential dual listing on a senior exchange in the United States or Australia.

不列顛哥倫比亞省溫哥華/ACCESSWIRE/2024年5月1日/MindBio Therapeutics Corp.(CSE: MBIO)(法蘭克福:WF6)(“公司” 或 “MindBio”)欣然宣佈,它已向各方、機構投資公司和經紀公司介紹MindBio,以在美國或澳大利亞的高級交易所進行雙重上市。

The Company has successfully completed Phase 1 and Phase 2a Clinical Trials with positive readouts and new discoveries. In February 2024, MindBio completed its Phase 2a trial of MB22001 in patients with Major Depressive Disorder. In this open label trial, patients experienced a 60% drop in depressive symptoms and 53% of patients entering the trial with MDD, at week 8 were in remission from their depression with a mean 14.1 point drop in MADRS score (Montgomery-Asberg Depression Rating Scale). Prior trial results using MB22001 recorded statistically significant improvements in total sleep time and quality of sleep and statistically significant increases in subjective feelings of "Happiness", "Social Connectivity", "Energy", "Creativity" and "Wellness" with reduced "Anger" and "Irritability". MB22001 is a promising and potential market disruptive medicine for treating depressive illness.

該公司已成功完成了1期和2a期臨床試驗,取得了積極的讀數和新的發現。2024 年 2 月,MindBio 完成了針對重度抑鬱症患者的 MB22001 2a 期試驗。在這項開放標籤試驗中,患者的抑鬱症狀下降了60%,進入MDD試驗的患者中有53%在第8周緩解了抑鬱症,MADRS評分(蒙哥馬利-阿斯伯格抑鬱評級量表)平均下降了14.1點。先前使用 MB22001 的試驗結果顯示,總睡眠時間和睡眠質量有統計學上的顯著改善,“幸福感”、“社交聯繫”、“精力”、“創造力” 和 “健康” 的主觀感受在統計學上顯著增加,“憤怒” 和 “煩躁” 減少了。MB22001 是一種治療抑鬱症的前景和潛在的市場顛覆性藥物。

The Company is now running two significant Phase 2B clinical trials with dosing underway and a third Phase 2B trial that has now also been approved in women's health. In a series of world firsts, each of these trials is approved for the take-home use of MB22001, a proprietary and self-titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take home microdosing.

該公司目前正在進行兩項重要的2B期臨床試驗,正在進行給藥,以及第三項2B期試驗,該試驗現已在女性健康領域獲得批准。在一系列世界首創中,這些試驗均獲准帶回家 MB22001,這是一種專有的可自滴定形式的麥角酸二乙酰胺(LSD),專爲安全帶回家的微劑量而設計。

MindBio will publish further readouts of its Phase 1 and 2A results in 2024 and expects the results of its Phase 2B trials to be announced in 2025. Management is now preparing and is in discussions with Clinical Research Organizations (CROs) for Phase 3 Clinical Trials with a 2025 start.

MindBio將在2024年發佈其1期和2A期結果的更多讀數,並預計其2B期試驗的結果將在2025年公佈。管理層目前正在爲2025年開始的3期臨床試驗做準備並正在與臨床研究組織(CRO)進行討論。

There are only a handful of public companies in the world that have progressed to Phase 2 and Phase 3 clinical trials in psychedelic medicines. MindBio is the most advanced clinical trial stage biopharma company listed on the Canadian Securities Exchange and the only company at this level that is not listed on a senior exchange. Given the success of its clinical trials and current program of works underway with multiple Phase 2B randomized controlled trials, management is actively having meetings with investment groups in Canada, United States and Australia for a potential dual listing on a senior exchange.

世界上只有少數幾家上市公司已進入迷幻藥物的2期和3期臨床試驗。MindBio是加拿大證券交易所上市的最先進的臨床試驗階段生物製藥公司,也是唯一一家未在高級交易所上市的該級別的公司。鑑於其臨床試驗的成功以及目前正在進行的多項2B期隨機對照試驗的工作計劃,管理層正在積極與加拿大、美國和澳大利亞的投資集團舉行會議,討論可能在優先交易所雙重上市的問題。

The Company will provide further updates to the market.

該公司將向市場提供進一步的最新信息。

Receive our latest updates here:
Follow MindBio on LinkedIn:
Follow CEO Justin Hanka on LinkedIn:

在此處接收我們的最新更新:
在領英上關注 MindBio:
在領英上關注首席執行官賈斯汀·漢卡:

For further information, please contact:

欲了解更多信息,請聯繫:

Justin Hanka, Chief Executive Officer
61 433140886
justin@mindbiotherapeutics.com

賈斯汀·漢卡,首席執行官
61 433140886
justin@mindbiotherapeutics.com

Media Inquiries
Kristina Spionjak
pr@hlthcommunications.com

媒體查詢
克里斯蒂娜·斯皮昂賈克
pr@hlthcommunications.com

About MindBio Therapeutics

關於 MindBio Therape

MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials. MB22001 is MindBio's lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder, both trials with positive top line data reported. Currently underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.

MindBio是一家領先的生物技術/生物製藥公司,專注於爲心理健康問題創造新的和新興的治療方法,並且正在進行世界上第一個帶回家的微劑量(MB22001)人體臨床試驗。MB22001 是 MindBio 的主要候選藥物,一種專有的可滴定形式的麥角酸二乙酰胺 (LSD),專爲帶回家的微劑量而設計。MindBio是迷幻藥物微劑量的領導者,正在通過臨床試驗推進其藥物和技術方案。MindBio開發了用於開發治療的多學科平台,參與迷幻藥物開發和數字療法,已完成了對80名健康參與者的1期臨床試驗,並完成了針對重度抑鬱症患者的2a期臨床試驗,這兩項試驗均報告了積極的頂線數據。目前正在進行兩項2B期試驗,一項針對經歷生存困擾的癌症患者,另一項針對重度抑鬱症患者。MindBio投資的研究爲開發經臨床驗證的新療法奠定了基礎,包括數字技術和干預措施,以治療抑鬱、焦慮和其他相關的心理健康狀況等使人衰弱的健康狀況。

Cautionary Note Concerning Forward-Looking Statements:

關於前瞻性陳述的警示性說明:

The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

該新聞稿包含適用證券法所指的 “前瞻性陳述”。前瞻性陳述可以通過以下詞語來識別:“預期”、“打算”、“預算”、“相信”、“項目”、“估計”、“預期”、“預期”、“戰略”、“未來”、“可能”、“可能”、“會”、“應該”、“將” 以及對未來時期或負面時期的類似提法或類似的術語, 以及將來通常使用的術語和有條件的術語.前瞻性陳述基於截至提供之日的假設。但是,無法保證此類假設會反映這些項目或因素的實際結果。

Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.

此外,一些已知和未知的風險因素可能導致公司的實際業績和財務狀況與前瞻性陳述中指出的業績和財務狀況存在重大差異。因此,您不應依賴這些前瞻性陳述中的任何一項。可能導致實際業績和財務狀況與前瞻性陳述中所述業績和財務狀況存在重大差異的重要風險因素包括:加拿大和澳大利亞的總體經濟、市場和商業狀況;市場波動;本新聞稿中描述的任何交易或事件的時間表出現不可預見的延遲。本警示聲明完全限定了所有前瞻性信息。

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

除非法律要求,否則公司沒有義務修改或更新任何此類前瞻性陳述,也沒有義務公開宣佈對本文包含的任何前瞻性信息進行任何修訂的結果,以反映未來的業績、事件或發展。

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

SOURCE: MindBio Therapeutics

來源:MindBio Therapeutic


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論